glp 1 and kidney Potential renoprotective effects of GLP1 receptor agonists. The A new study offers compelling

Metabolic Health Some research has explored whether ALCAR may support insulin sensitivity and glucose metabolism

A massive adoption of GLP-1 drugs in leading markets and growth areas (notably Asian markets) could be a significant blow to many food companies

Considering that some of the GLP-1R agonists also decrease body weight, these have received approval for the treatment of obesity in humans [for a review, see Srivastava and Apovian (2018)]

New Level II HCPCS Codes Final Rule Comment Solicitation Consistent with past practice, we are soliciting comments on the new Level II HCPCS codes that will be effective January 1, 2026, in the CY 2026 OPPS/ASC final rule with comment period, thereby allowing us to finalize the status indicators and APC assignments for the codes in the CY 2027 OPPS/ASC final rule with comment period